Rallybio Reveals Details of Two Pipeline Programs with the Potential to Transform the Lives of Patients with Rare Diseases
– RLYB212: A Novel Monoclonal HPA-1a Antibody for the Prevention of a Potentially Life-Threatening Rare Disease that Impacts Fetuses and Newborns –
– RLYB116: A Novel Small Protein Inhibitor of Complement C5 for the Treatment of Patients with Severe …